The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at higher risk of severe disease, but will require vaccine makers to conduct major new clinical trials before approving them for wider use.

O n May 20, the federal government announced a major shift in how it plans to review and recommend COVID-19 vaccines for Americans. Among the changes: when manufacturers want to u

Top health officials were aware of and actively took steps to “delay warning the public” for months in 2021 about the potential risks of patients suffering from heart-related

Previously, updated COVID vaccines had been recommended annually by the CDC for everyone over the age of 6 months. The CDC has historically set vaccine recommendations, while the FDA determines which vaccines to authorize or approve after being deemed safe and effective.

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr. Philip Dormitzer, may have “conspired to withhold public

A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations provided by a rival drugmaker.

The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit future shots to older Americans and people at higher risk of serious Covid-19 infection.

Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or whether they should be recommended only for people at increased risk.

The FDA will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to green-lighting shots that have been recommended broadly to the public.